A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
University of Nebraska
Perspective Therapeutics
Bristol-Myers Squibb
HiFiBiO Therapeutics
Tango Therapeutics, Inc.
Tango Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Ipsen
Actym Therapeutics, Inc.
Travera Inc
Azienda Ospedaliera di Padova
University of Pittsburgh
PharmaMar
Columbia University
Instituto do Cancer do Estado de São Paulo
Ipsen
Ascentage Pharma Group Inc.
National Institutes of Health Clinical Center (CC)
MacroGenics
Shenzhen BinDeBio Ltd.
Masonic Cancer Center, University of Minnesota
Novartis
Stanford University
Valerio Therapeutics
Valerio Therapeutics
Precision Therapeutics
Astellas Pharma Inc